{"schema_version":"secwatch.filing_event.v1","accession":"0000939767-24-000025","form_type":"8-K","ticker":"EXEL","cik":"0000939767","company_name":"EXELIXIS, INC.","filed_at":"2024-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.367305+00:00","generated_at":"2026-06-06T08:53:49.735855+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Exelixis Q4 2023 revenue $479.7M, GAAP EPS $0.27, non-GAAP $0.33; FY revenue $1.83B","bullets":["Total Q4 revenues $479.7M (up from $423.9M YoY); cabozantinib net product revenues $429.3M.","GAAP diluted EPS $0.27 (Q4) and $0.65 (FY); non-GAAP diluted EPS $0.33 (Q4) and $0.90 (FY).","FY 2023 total revenues $1.83B, up 14% from $1.61B; net product revenues $1.63B.","R&D expenses $244.7M (Q4) vs $336.8M YoY; SG&A $131.4M vs $119.3M YoY.","Pipeline: regulatory strategies for cabozantinib label expansions; MSN IP litigation ruling expected spring 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000939767-24-000025","json":"https://secwatch.observer/filing/0000939767-24-000025.json","markdown":"https://secwatch.observer/filing/0000939767-24-000025.md","text":"https://secwatch.observer/filing/0000939767-24-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/939767/000093976724000025/0000939767-24-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/939767/000093976724000025/exel-20240206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T08:53:49.735855+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dad3e8ce495f5f70993de0d1d2f34181661096ae","claim":"EXELIXIS, INC. reported financial results for quarter and year ended December 31, 2023.","evidence_excerpt":"On February 6, 2024, Exelixis, Inc. (Exelixis) issued a press release announcing its financial results for the quarter and full year ended December 29, 2023, and providing a corporate update. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/939767/000093976724000025/0000939767-24-000025-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter and year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}